Finding new drugs again can improve the treatment of Parkinson's disease

Researchers have developed a new drug that can limit the progression of Parkinson's disease.

Previously, the symptoms of Parkinson's disease were often controlled by selective dopamine receptor drugs.

Although these drugs are very useful in the early stages of Parkinson's disease, they tend to reduce efficacy in later stages of the disease.

In this study, researchers used a preclinical model of Parkinson's disease to compare the effectiveness of dopamine agonist ropinirole with their new experimental drug called D-512.

In experiments with animal models, the study published in the British Journal of Pharmacology showed that the drug D-512 is more effective than ropinirol in the treatment of symptoms of Parkinson's disease.

David Lindenbach, Binghamton University - New University said: "We were surprised to discover that our new compound, D-512, is better than the widely used drug, ropinirol, in Symptoms of Parkinson's symptom relief and uptime .

The researchers also noted that D-512 may have fewer side effects than current drugs. When patients take anti-Parkinson drugs, over time, drugs that are overactive can be difficult to control, called dyskinesia in the body.

Researchers are currently studying D-512 in the preclinical phase.